Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

News provided by

Oct 02, 2013, 07:43 ET

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

http://www.reportlinker.com/p01658520/Treating-Refractory-Hematological-Malignancies-–-Multiple-Myeloma-MM-New-Treatment-Options-Driving-In-Licensing-and-MA.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

1. Executive Summary

2. Investment Drivers of The Select Companies Covered

3. Multiple Myeloma (MM)

3.1 Disease Overview

3.2 Current Standard of Care

3.2.1 Relapsed and/or Refractory Multiple Myeloma (RRMM)

a Competitive landscape – RRMM

b Data Comparison – RRMM

3.2.2 Newly Diagnosed Multiple Myeloma (NDMM)

a Competitive landscape – NDMM

b Data Comparison – NDMM

4. Novel Targets including Monoclonal Antibodies And Small

Molecules Offer In-Licensing Opportunity

4.1 Overview of Targets involved

4.2 Late-stage pipeline – Small Molecules

4.2.1 Kyprolis (carfilzomib)

4.2.2 POMALYST / IMNOVID (pomalidomide)

4.2.3 Ixazomib (MLN9708)

4.2.4 Panobinostat

4.2.5 Obatoclax

4.2.6 SNS01-T

4.2.7 Oprozomib

4.3 Late-stage pipeline – Monoclonal Antibodies

4.3.1 Elotuzumab

4.3.2 Siltuximab

4.3.3 Daratumumab

4.3.4 MOR202

5. Ongoing Clinical Trial Details of Key Drugs in the Pipeline

6. Key Milestones

7. MPA View on the Future of the Drugs in the Late-Stage

pipeline7.1 Launch Timeline and Commercial Opportunity of Late-stage

Pipeline (RRMM and NDMM)

7.2 Drivers of M&A / Licensing Deals in MM

7.2.1 Select M&A Deals in Last 5 Years – 2007 to 2012

7.2.2 Select Licensing Deals in Last 5 Years – 2007 to 2012

7.2.3 M&A and Licensing Deals Opportunity

8. Detailed Company Analysis (incl. Clinical Data of Drugs,

Milestones, and Valuation)

8.1 Amgen (AMGN, Post-acquisition of Onyx pharma)

8.1.1 Investment Drivers

8.1.2 Longer-term growth

a Acquisition of Onyx and its pipeline discussion

8.1.3 Late-stage pipeline

a Denosumab label expansion

b AMG 145 – Data presented at ESC 2013 and its comparison

with REGN/SNY's REGN727/SAR236553

c Collaboration agreement with Servier

d Talimogene laherparepvec (T-VEC)

e Trebananib (AMG 386)

8.1.4 Opportunity in Emerging market and Expansion in other

Geographies

8.1.5 Key Milestones

8.1.6 NPV Valuation

8.2 Celgene (CELG)

8.2.1 Investment Drivers

8.2.2 Growth from Marketed products and Label expansion

a Revlimid – Geographic expansion and Generic threat after 2019

b Pomalyst – Current market scenario and competition to Kyprolis

c ABRAXANE – Label expansion

d Vidaza – Oral formulation and Generic entry in the US market

e Inflammation pipeline to start contributing to sales by 2014

f Novel Early stage products 8.2.3 Key Milestones

8.2.4 NPV Valuation

8.3 MorphoSyS

8.3.1 Investment Drivers

8.3.2 Recent Alliances

a. MOR / CELG for MOR202 (PhI/II, RRMM, anti-CD38 mAb)

b. MOR/ GSK for MOR103 (PhII, RA, anti-GM-CSF mAb)

8.3.3 Clinical Data from partnered pipeline products in 2H13 and

Beyond

a. Bimagrumab (BYM338, PhII, COPD, Cancer, ActRIIB, sIBM)

b. BHQ880 (PhII, MM, anti-DKK-1 mAb)

c. Gantenerumab (IgG, PhIII, Alzheimer's disease)

8.3.4 Other Partnered programs

8.3.5 Novel proprietary technology platforms

8.3.6 Key Milestones

8.3.7 NPV Valuation